The CEO of the German firm, which developed the vaccine with the American company, said in a conversation with "Reuters" that the FDA may grant the long-awaited approval as early as next month.
The medical regulatory authorities in the United States and Europe may approve the corona vaccine of the Pfizer and Biontech companies in mid-December, the German firm's CEO said last night (Wednesday).
Documentation: Vaccine production chain // Photo: Pfizer
In an interview with Reuters, Biontech CEO Ogor Shahin said that if all goes well, the US FDA may grant approval by mid-December.
"It depends on the requests we receive and whether all the conditions are met," the CEO said. Earlier on Wednesday, Pfizer and Biontech unveiled updated results for the third phase of the vaccine trial.
According to these results, the vaccine effectiveness stands at 95%.
The vaccine also showed efficacy among a variety of age groups and no significant side effects appeared.
